王德深

一、基本情况

姓名：王德深

学历：中山大学临床医学博士

职称：主任医师、博士生导师

专长：消化系统肿瘤的内科治疗和研究

出诊时间：周二下午225诊室（越秀）；周四上午223诊室（越秀）；周三下午408诊室（黄埔）

二、个人简介

医学博士、主任医师、博士生导师。主攻消化系统肿瘤（结直肠癌，胃食管肿瘤，胆胰肿瘤，胃肠胰神经内分泌肿瘤）的内科治疗、新药及基础转化研究。近年来主持国家自然科学基金2项、广东省自然科学基金杰出青年项目1项和高校青年教师团队项目1项，参与国家重点研发计划和广州市产学研协同创新重大专项等。以第一/通讯（共同）作者在Gut, JAMA Oncol, Drug Resist Updat, PLoS Med, Cancer Res等学术期刊发表论文20余篇。成果分别改写国际/国内指南3项，包括MASCC/ESMO/CSCO指南等，被美国Up to date临床循证医学数据库收录。研究多次入选ASCO和ESMO等国际会议壁报和口头报告，参编肿瘤专业书籍1部，授权专利1项，担任国家自然科学基金评审专家、《Drug Resistance Updates》杂志编委及《American Journal of Gastroenterology》、《eBioMedicine》等杂志审稿专家。获得“2012年教育部博士学术新人奖”、参与的“分子标志物在消化系统肿瘤个体化诊疗中的应用研究”项目获中华医学会科技奖等省部级一等奖3项。

三、学术兼职

（1）中国抗癌协会肿瘤临床化疗专委委员

（2）广东省抗癌协会分子靶向治疗专委常委

（3）广东省抗癌协会大肠癌专委青委常委

（4）广东省精准医学应用学会胃肠肿瘤分会常委

（5）广东省基层医药学会结直肠专委委员

（6）广东省临床医学学会消化肿瘤综合治疗青委常委

（7）国家自然科学基金委医学科学七处基金委评议人

（8）《Drug Resistance Updates》杂志编委

四、代表论文

（1）Ye LF, …, Li YH*, Xu RH*, Wang DS*. Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA. Drug Resist Updat. 2022 Sep 29; 65:100883.

（2）Wang DS^#, …, Xu RH. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut, 2019 Jul;68(7):1152-1161.

（3）Wang DS^#, …, Xu RH*, Li YH*. Cetuximab Plus FOLFOXIRI Versus Cetuximab Plus FOLFOX as Conversion Regimen in RAS/BRAF Wild-type Patients with Initially Unresectable Colorectal Liver Metastases (TRICE trial): A Randomized Controlled Trial. PLoS Med. 2024 May 10;21(5):e1004389. 

（4）Liu GY#, Li WZ#, Wang DS^#, …, Xiang YQ*. Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022 Apr 1;8(4):553-561.

（5）Zheng YQ, …, Wang DS*. Endoscopic excision as a viable alternative to major resection for early duodenal cancers: A population-based cohort study. Int J Surg. 2022 Apr 29:106644.

（6）Wang DS^#, …, Li YH. Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial. JAMA Netw Open. 2021 Apr 1;4(4): e215250.

（7）Liu J, …, Wang DS*, Xu RH*, Ju HQ*. The macrophage-associated lncRNA MALR facilitates ILF3 liquid-liquid phase separation to promote HIF1α signaling in esophageal cancer. Cancer Res (2023) 83 (9): 1476–1489.

（8）Wen L, …, Wang DS*, Li YH*. Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring POLE exonuclease domain mutation. J Immunother Cancer. 2022 Jul;10(7): e004487.

（9）Wang DS^#, …, Li YH, Xu RH. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases. Theranostics 2021; 11(14):7018-7028.

（10）Liang JY#, Wang DS^#, …, Li YH. A Novel Ferroptosis-related Gene Signature for Overall Survival Prediction in Patients with Hepatocellular Carcinoma. Int J Biol Sci. 2020 Jul 6;16(13):2430-2441.

（11）Wang W, …, Wang DS*. Heterogeneity and evolution of tumour immune microenvironment in metastatic gastroesophageal adenocarcinoma. Gastric Cancer. 2022 Nov;25(6):1017-1030. 

（12）Zheng JB, …, Wang DS*. Glucose metabolism inhibitor PFK-015 combined with immune checkpoint inhibitor is an effective treatment regimen in cancer. OncoImmunology. 2022 May 25;11(1):2079182.

五、编写书籍

（1）De-Shen Wang, Hong-May Sim, Suresh V. Ambudkar, and Zhe-Sheng Chen, “ABC Transporter Modulatory Drugs from Marine Sources: A New Approach to Overcome Drug Resistance in Cancer”, Volume Title: Resistance to Targeted ABC Transporters in Cancer (Hardback) Edited by Thomas Efferth, ISBN: 978-3-319-09800-5 (Print) 978-3-319-09801-2 (Online), Book Title: Resistance to Targeted Anti-Cancer Therapeutics, Springer Publishers, Inc. 

六、发明专利授权

（1）徐瑞华，王德深，刘泽先，鲁运新。司美替尼在治疗对HER2靶向治疗耐药的胃癌方面的应用（公开号：CN108295066A）